Title
Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas

Permalink
https://escholarship.org/uc/item/2wp5p2ch

Journal
CURRENT NEUROPHARMACOLOGY, 15(1)

ISSN
1570-159X

Authors
Hashizume, R
Gupta, N

Publication Date
2017

DOI
10.2174/1570159X14666160523144117

Peer reviewed
Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas

Rintaro Hashizume¹ and Nalin Gupta²,*

¹Department of Neurological Surgery, Northwestern University, Chicago, IL, USA; ²Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143-0520, USA;

Abstract: Background: Diffuse intrinsic pontine gliomas represent a unique subtype of primary brain tumors occurring in a specific location and age. Their growth demonstrates early invasion and, following diagnosis, rapid growth not responsive to common therapies. Until recently, the genetic and cellular basis of these tumors was unknown. Genetic evidence implicates mutations in the histone genes in the origin of these tumors.

Methods: Surgical biopsies performed on selected patients have resulted in the establishment of anatomically accurate mouse models that have been used to examine patterns of growth and response to new therapeutic agents.

Results: Human derived pontine glioma models recapitulate the invasive patterns of growth. The grade of the original tumor affects the latency of tumor growth after implantation.

Conclusion: The use of human-derived xenograft models allows for improved pre-clinical testing of new therapeutic targets in a tumor- and organ-specific manner.

Keywords: Brainstem glioma, xenograft model, infiltrating astrocytoma.

INTRODUCTION

Pediatric brain tumors are rare, occurring in only several thousand children in the United States each year. Although hematologic malignancies are more common, brain tumors have poorer responses to therapy and survivors often have substantial morbidity and longterm cognitive side effects. The genetic characterization of some tumor types, such as medulloblastoma, has progressed dramatically in the past ten years [1]. However, other tumor types are less well defined.

Tumors arising in the brainstem represent approximately 10% of all brain tumors in children. Although there is a range in the malignancy of these tumors, the majority occur in a restricted anatomic area, that of the ventral pons. These tumors, known as diffuse intrinsic pontine gliomas (DIPG), are typically malignant in nature and virtually all patients die within two years after diagnosis [2]. The factors that contribute to the dismal prognosis include extensive infiltration of the brainstem at the time of diagnosis, an anatomic location which precludes surgical resection, and resistance to most types of conventional cancer therapeutics. A large number of Phase I studies conducted over the past twenty years have failed to demonstrate any improvement in survival, or even any response, in the majority of these patients. Indeed, the only modality of therapy that prolongs survival, fractionated radiotherapy, has not changed in several decades.

Because of the typical location of DIPGs, surgical biopsy was felt to be redundant, and diagnosis was made on the basis of features identified on imaging studies [3]. A consequence of this change in practice was that cell and/or tissue resources that could be used for preclinical testing were rarely available. In contrast to the progress in the understanding of the genetics of adult malignant glioma [4], it could be argued that the lack of DIPG tissue samples has hindered progress in identifying underlying oncogenic steps. Recently, genetic analyses of tissues obtained at autopsy have identified a number of DIPG gene and chromosomal alterations, including mutation of the gene encoding histone H3, which is rare among adult malignant gliomas [5]. These results support the existence of key genetic differences between adult gliomas and DIPGs, thereby underscoring the need for thorough molecular profiling of the brainstem tumors, for facilitating improved understanding of associated molecular biology, and the related development of rational therapeutic approaches for treating DIPG.

RELEVANT ANATOMIC LOCATION

The use of animal models in cancer therapeutics should facilitate pre-clinical translation and testing of new agents, prior to entry into human clinical trials. For this important reason, it is essential that models recapitulate the human
disease as faithfully as possible. Obviously, there are limitations in terms of organ size and animal physiology that cannot be avoided. However, for many in vivo screening assays, widely divergent tumor cell lines are used and the results extrapolated to tumor types far removed from the cell line being tested.

Historically, pre-clinical testing of new therapeutic agents was performed in a variety of standard in vivo models, starting with flank, subcutaneous tumors, and then moving to standard intracranial tumor models. It is clear that subcutaneous models may permit an evaluation of general pharmacokinetics, but they do not represent an ideal tumor model to test organ-specific therapeutic response [6]. Furthermore, standard tumor models often used well-established cell lines (e.g. U87, U251) that often grew in a pattern that did not resemble a primary brain tumor in any way. A central feature of DIPGs are their extensive degree of infiltration; a feature that may result from absence of specific types of proteoglycan molecules in the tumor microenvironment [7]. Although valuable information can be gained from broad cellular effects, it is also clear that biologically-targeted therapeutics need to be tested in genetically faithful systems.

Most intracranial tumors are grown in a location corresponding to the telencephalon, or the deep frontal lobe. The first challenge to examining the biology of DIPGs was to grow tumors in the appropriate anatomic location. Previously, there were few attempts using the brainstem as a target for cell deposition because of the small size of the rodent pons, and perceived side effects from tumor growth in that location. The initial steps were the development of targets and tools that would allow deposition of cells into the rodent brainstem. Because of the increased size of the rat brainstem, this animal type was better suited to the initial technical refinement [8]. This work was subsequently extended to use mice which were less expensive and allowed the use of genetically modified animals if necessary [9]. Using modified entry measurements (a burr hole was placed 1.0 mm behind the lambda, and 9.6 mm deep from the inner surface of the skull), it was possible to obtain reliable tumor growth in the rodent brainstem. The consistency of the implanted tumor cell method facilitates pre-clinical testing.

IMAGING OF XENOGRAFTED TUMORS

Tumor growth in the brainstem, as in other locations, usually leads to symptoms and animal demise. The availability of non-invasive tumor imaging greatly facilitates measurement of tumor growth and improves the ability to perform therapeutic testing. There are different techniques that can be used for animal in vivo imaging including positron emission tomography (PET) and single-photon emission tomography (SPECT) [10]. These are based on the use of radionuclides which has substantial technical requirements. Magnetic resonance imaging (MRI) provides excellent anatomic resolution but can be expensive, particularly when longitudinal experiments are planned [11].

Bioluminescence imaging (BLI) relies on the detection of the emission of photons based on energy-dependent reactions catalyzed by cells or organisms that have been genetically modified to express luciferase. Transfection of brain tumor cell lines with a lentiviral vector containing firefly luciferase (Fluc) allowed reproducible imaging using the Xenogen IVIS Lumina system coupled. Testing with agents such as temozolomide showed that luminescence in rodents receiving TMZ treatment was substantially reduced when the treatment was completed [12]. BLI measurements are a good surrogate of tumor volume, particularly when luciferase expression is consistent throughout the tumor. From a practical perspective, BLI allows a reduction in the sizes of animal cohorts when planning pre-clinical therapeutic testing.

PATIENT- DERIVED TUMOR MODELS

Patient-derived cell lines are derived from many primary tumor types. However, because of the rarity of fresh tissue available from DIPGs, the first true cell lines were obtained from autopsy specimens [13]. These cells were grown as neurospheres in serum-free media supplemented with epidermal growth factor (EGF) and fibroblast growth factor (FGF); subsequent growth was improved with the addition of platelet-derived growth factor (PDGF). Examination of these cells supported a role for hedgehog (Hh) signalling. From a conceptual perspective, cells obtained at autopsy are by definition obtained from patients well after recurrence after substantial therapeutic intervention. It would be ideal to evaluate tissues obtained directly from initial surgical biopsy. A technical limitation of the surgical biopsy obtained from DIPGs was the very small size with individual biopsy specimens measuring only 3-4 mm in length, and less than 1 mm in diameter. Nevertheless, starting from small fragments of tissue, it is possible to establish a primary cell lines that are tumorigenic in animal models [14].

One difficulty of this approach was highlighted in one case where the diagnostic histopathology of the tissue obtained from a surgical biopsy was consistent with an infiltrative astrocytoma, WHO grade II [14]. Based on previous experience with establishing primary cell cultures from low grade glial tumors, we anticipated this tissue would have a low likelihood of engraftment, and would likely become senescent during extended cell culture. Therefore, we transduced SF7761 cells with a retrovirus vector containing hTERT (human telomerase reverse transcriptase) for cell immortalization. This step avoided senescence and facilitated growth of the cells both in vivo and in vitro (Fig. 1). A limitation of this approach is that a genetic variant is introduced that was not present in the original tumor.

Examination of corresponding xenografts in rat brainstems demonstrated a diffusely infiltrating tumor, similar to that observed in the surgical biopsy specimen. Xenograft tumor cells appeared to extend through the pons, and in some cases to expand the structure, also similar to that observed in patients with DIPG.

MOLECULAR FEATURES

Recent papers have demonstrated that there are unique alterations in pediatric gliomas as compared to their adult counterparts [15]. Similarly, there are regional differences between tumors that arise in the hindbrain as compared to
the cerebral hemispheres, such as has been described for ependymomas arising in different CNS locations [16]. The relative percentage of self-renewing cells also appears to be increased in most pediatric CNS tumors as compared to tumors obtained from adult patients [17].

Until very recently, none of the signaling pathways involved in DIPG formation were known. Two recent studies of pediatric high-grade gliomas noted that PDGFRA amplification occurred in 29-36% of DIPGs [15a, 18]. Up-regulation of PDGFR signaling in Nestin+ cells of the IVth ventricle subventricular zone [19], or cells of the dorsolateral pons [20] results in formation of glioblastoma in mouse models. Our analysis reveal that SF7761 cells have elevated PDGFRα and Rb, but lack expression of the tumor suppressor p16NK4a. These cells also express Nestin and Olig2 [14]. Isolation of primary cell cultures obtained at the time of biopsy also may play a role in testing tumor response to therapy. Using cell cultures obtained from surgical biopsies, the PDGF receptor inhibitor dasatinib was tested and found to inhibit cell proliferation and invasion [21].

Gliomas arising in children and young adults in midline structures such as the brainstem and diencephalon have a high frequency of mutations in the H3F3 gene [5b, 15b, c, 22]. These mutations result in modification of epigenetic marks that ultimately affect gene transcription. The consistency of the H3K27M mutation in DIPG is striking, as is the profound effect on the regulation of many gene targets [23]. A substantial percentage of DIPG tumors are also known to carry mutations in the ACVR1 gene, when mutated in the germ line causes a pathologic predisposition towards ossification of soft tissues [24]. The direct relationship between this gene mutation and DIPG oncogenesis is unclear.

Cell lines isolated from DIPG also carry the H3K27M mutation which facilitates both in vitro and in vivo examination of the effects of this mutation. The specific feature associated with the H3K27M mutation is an alteration in the level of histone di- and tri-methylation; a modification which can be targeted by agents that regulate histone methylation [25]. One of these agents, GSKJ2, is an
active inhibitor of the histone demethylases, and in part, can reverse the transcriptional, and tumorigenic effects of the K27M mutation.

LIMITATIONS

A fundamental limitation with all human-based xenograft model systems is the use of immunodeficient animals. The absence of an attenuated host response clearly modifies tumor growth both in terms of tumor morphology, and efficiency of engraftment. While certain assumptions are acceptable in the interpretation of results from xenografted models, achieving relevant conclusions in the area of therapeutic assessment is a challenge. Certain fundamental biologic features are likely to be similar in immunodeficient and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and response to immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent animals, but others such as tumor associated inflammation, tissue invasion, response to injury, and immunocompetent

An important conceptual difference between xenografted tumors and de novo tumors is the process of tumor initiation. Presumably, there are early genetic changes that trigger deregulated tumor growth in the host tissue. In other tumor types such as medulloblastoma, genetic changes can be constructed in transgenic mice that result spontaneous tumor formation indistinguishable from the human disease [26]. The onset of tumor formation makes pre-clinical testing more difficult but from a biologic perspective, transgenic models should be considered more accurate in terms of tumor and host biology.

SUMMARY

Human-derived animal models provide a mechanism to study biologically relevant tumors in an in vivo setting. Coupled with anatomically relevant sites and tumors that maintain some aspects of the original tumor biology, appropriate results can be derived. These models are particularly valuable for pre-clinical screening of therapeutic agents, although their limitations should be clearly recognized.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by the Pediatric Brain Tumor Foundation Institute Award to the University of California San Francisco.

REFERENCES


Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas

Current Neupharmaco, 2016, Vol. 14, No. 0 5


